Compare Centene Corp (CNC) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Centene Corp vs Tenet Healthcare Corporation — how do they compare? Centene Corp trades at $66.47 (market cap $33.93B), while Tenet Healthcare Corporation trades at $192.18 (market cap $15.82B). The key difference: Centene Corp is far larger — about 2.1× Tenet Healthcare Corporation's market cap, and Centene Corp is trading nearer its 52-week high, Tenet Healthcare Corporation nearer its low. Which is the better fit depends on your goals.
| CNC | THC | |
|---|---|---|
Market Cap | $33.93B | $15.82B |
Sector | Health | Health |
52-Week High | $68.72 | $244.80 |
52-Week Low | $25.21 | $148.38 |
Enterprise Value | $26.56B | $26.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Centene Corporation (CNC) trades at $68.29, up 1.4% with strong technical momentum and bullish moving average signals. The stock shows impressive 66% YTD gains, supported by recent contract renewals and margin recovery initiatives. Despite negative 2025 net income of -$6.67B, valuation metrics remain attractive with P/E of 8.06 and P/S of 0.17. Analyst consensus is strongly bullish with 61% buy ratings and $66.07 price target.
Centene presents a compelling value opportunity with low valuation multiples and strong operational cash flow of $5.09B. Key risks include ongoing margin pressure and Medicaid contract dependency. The company's AI-driven cost controls and recent Illinois Medicaid renewal provide catalysts for earnings recovery, though healthcare regulatory changes remain a concern for long-term stability.
Tenet Healthcare (THC) trades at $194.81, down 4.62% today, but maintains strong fundamentals with consistent earnings beats and attractive valuation metrics. The stock shows robust profitability with 37.87% ROE and 7.79% net margin, supported by growing outpatient care operations. Technical indicators suggest near-term bearish pressure with key support at $191 and resistance at $198. Recent analyst coverage remains overwhelmingly positive with 81% buy ratings and a $235.88 consensus target.
THC presents a compelling value opportunity with below-market P/E of 9.55 and strong earnings momentum, though technical weakness and upcoming Q2 earnings on July 24 create near-term uncertainty. The expanding ambulatory care segment and defensive healthcare positioning during geopolitical tensions support long-term growth, while debt levels and hospital industry challenges remain key monitoring points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Centene Corp
Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.
Read more on CNC →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
